SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jim Bishop who started this subject9/11/2003 10:24:17 AM
From: Jim Bishop  Read Replies (1) of 150070
 
WILMINGTON, N.C., Sept. 11 /PRNewswire-FirstCall/ -- aaiPharma Inc.
(Nasdaq: AAII) announced that it received confirmation today of U.S. Food and
Drug Administration (FDA) approval of Darvocet A500(TM) (propoxyphene
napsylate and acetaminophen) for the treatment of mild to moderate pain.
Darvocet A500(TM) is the only propoxyphene napsylate/acetaminophen combination
product currently FDA approved that contains a lower (500 mg) dose of
acetaminophen combined with 100 mg of propoxyphene napsylate, the same dose of
propoxyphene napsylate found in Darvocet-N(R) 100. This new product will
provide patients a unique Darvocet(TM) formulation with the safety benefits of
less acetaminophen and the full power of propoxyphene.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News